Karyopharm Therapeutics (KPTI) Earnings Date & Reports

Key Takeaways

• Karyopharm Therapeutics has not yet released its third-quarter 2026 results, which had been widely expected around late October to early November 2026.
• Consensus estimates pointed to quarterly revenue of roughly $33.5 million, with analysts projecting a net loss per share clustered around $0.95 to $1.16.
• On November 2, 2026, the company filed for Chapter 11 bankruptcy protection and announced a planned merger with Ayrmid Ltd., with the filing coming in lieu of the expected third-quarter earnings release.
• Karyopharm reported about $441.5 million in debt and secured commitments for up to $55 million in debtor-in-possession (DIP) financing, a loan that lets a bankrupt company keep operating during restructuring.
• In its most recent reported quarter (Q2 2026), Karyopharm posted a $2.32 per-share loss on $33.4 million in revenue, with U.S. XPOVIO (selinexor) net product revenue of $30.8 million.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover Trending AI Robots for AI-driven market insights.

Earnings Context and Why It Matters

This earnings period carries unusual weight because Karyopharm's financial future, not just its operating results, is now in question. The company has been navigating mounting liquidity pressure while working to expand its lead therapy, XPOVIO (selinexor), an inhibitor of the exportin 1 (XPO1) protein, into myelofibrosis. After ending Q2 2026 with only $65.4 million in cash and a loan payment looming, management warned it might be unable to continue as a going concern. The decision to file for Chapter 11 protection on November 2, 2026, rather than report Q3 results, fundamentally reframes what investors are evaluating: near-term revenue trends, cash runway, and the terms of a court-supervised sale that could leave existing shareholders with little recovery.

Earnings Expectations

Heading into the quarter, Wall Street's consensus anticipated roughly $33.5 million in third-quarter revenue, down from $44.04 million a year earlier. Analysts' loss-per-share forecasts ranged from about $0.78 to $1.16, reflecting continued operating losses. These estimates built on a mixed recent track record: Karyopharm beat revenue and earnings expectations in Q1 2026, then missed badly on earnings in Q2 2026, posting a $2.32 per-share loss versus a $1.31 consensus. Full-year 2026 guidance, reaffirmed in August, called for $130 million to $150 million in total revenue and combined R&D (research and development) plus SG&A (selling, general and administrative) spending of $230 million to $245 million. The November 2 bankruptcy filing means those figures may now take a backseat to restructuring terms.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking volatile, event-driven names like Karyopharm, this kind of tool can help surface signals across the broader biotech landscape.

Market Reaction and Investor Sentiment

Sentiment has deteriorated sharply. On November 2, 2026, shares plunged roughly 83% to around $0.11 following the Chapter 11 filing, leaving the company with a market capitalization of only about $2.5 million. The reaction reflects a shift in how the stock is valued: rather than trading on Xpovio sales or pipeline potential, Karyopharm is now being evaluated on the likely recovery available to equity holders under a restructuring. Analysts at Rodman & Renshaw downgraded the stock and withdrew their price target, noting that secured lenders and noteholders are positioned to recover first, so any value left for common shareholders "could be minimal." With the planned Ayrmid merger expected to close in the first quarter of 2027, near-term trading is likely to remain driven by restructuring headlines rather than fundamentals.

Forward Outlook and Key Factors to Monitor

Investors should watch several developments in the months ahead. The first is the bankruptcy court's approval of the up-to-$55 million DIP financing, which would let Karyopharm fund day-to-day operations during the restructuring. A court-supervised sale process is central to the plan, with Ayrmid Ltd. serving as the lead bidder, though competing bids may still emerge.

A second key item is the status of Karyopharm's myelofibrosis program. The company had submitted a supplemental new drug application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for selinexor in combination with Incyte's Jakafi, with a potential decision expected in early 2027. How that regulatory review proceeds could influence the value assigned to the business in any sale.

Finally, monitor whether Karyopharm eventually reports its third-quarter financials. The absence of a traditional Q3 release means investors lack an updated view of Xpovio's U.S. sales trajectory and the company's cash position heading into restructuring. Until more details emerge, the central questions are the auction's outcome, the treatment of existing shareholders, and whether any competing bidder improves on Ayrmid's proposal.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations